CROSS LICENSE AGREEMENTCross License Agreement • August 24th, 2015 • Mirna Therapeutics, Inc. • Pharmaceutical preparations • Delaware
Contract Type FiledAugust 24th, 2015 Company Industry JurisdictionThis Cross License Agreement (this “Agreement”) is made as of the Effective Date (as such term is defined below) by and between Asuragen, Inc., a Delaware corporation with its principal offices at 2150 Woodward St., Austin, Texas 78744 (“Asuragen”) and Mirna Therapeutics, Inc., a Delaware corporation with an office at 2150 Woodward Street, Austin, Texas 78744 (“Mirna”); (each of Asuragen and Mirna is referred to herein as “Party” and together as the “Parties”).
CROSS LICENSE AGREEMENTCross License Agreement • April 4th, 2014 • Mirna Therapeutics, Inc. • Pharmaceutical preparations • Delaware
Contract Type FiledApril 4th, 2014 Company Industry JurisdictionThis Cross License Agreement (this “Agreement”) is made as of the Effective Date (as such term is defined below) by and between Asuragen, Inc., a Delaware corporation with its principal offices at 2150 Woodward St., Austin, Texas 78744 (“Asuragen”) and Mirna Therapeutics, Inc., a Delaware corporation with an office at 2150 Woodward Street, Austin, Texas 78744 (“Mirna”); (each of Asuragen and Mirna is referred to herein as “Party” and together as the “Parties”).